What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
Pojsakorn Danpanichkul, Kanokphong Suparan, Donghee Kim, Karn Wijarnpreecha
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of the world's adult population. While it is associated with obesity and metabolic syndrome, emerging evidence has shown that a substantial number of MASLD patients have a normal body mass index ("lean individuals with MASLD"). In this article, we provide an overview of the definition, epidemiology, pathogenesis, and clinical outcomes associated with lean individuals with MASLD and updates on current management.
Topics & Concepts
MedicineMetabolic syndromeDiseaseObesityEpidemiologyPathogenesisFatty liverBench to bedsideBody mass indexBioinformaticsIntensive care medicineInternal medicineBiologyMedical physicsLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsDiet, Metabolism, and Disease